-
103
Reference
1. Zubay, G. L., Biochemistry; 4Ed, Worthington, R.,
Ed.:McGraw-Hill
Companies, Inc.: Dubuque, 1998.
2. Dugas, H., Bioorganic Chemistry; Cantor, C. R., Ed.;
Springer: New York,
1996.
3. Gaál, J.; Hermecz, I., Inhibitors of Monoamine Oxidase B:
Pharmaclogy
and Clinical Use in Neurodegenerative Disorders; Szelenyi, I.,
Ed.: Birkhauser:
Boston; Berlin, 1993.
4. Silverman, R. B., Mechanism-based enzyme inactivators.
Methods in
Enzymol. 1995, 249, 240.
5. Silverman, R. B., Radical Ideas about Monoamine Oxidase. Acc
Chem Res
1995, 28, 335.
6. Shaoyong Ke; Zhong Li; Xuhong Qian.,
1,3,4-Oxadiazole-3(2H)-
carboxamide derivatives as potential novel class of monoamine
oxidase (MAO)
inhibitors: Synthesis, evaluation, and role of urea moiety.
Bioorg Med Chem
2008, 16, 7565-7572.
-
104
7. Kalgutkar, A. S.; Dalvie, D. K.; Castagnoli, N., Jr.; Taylor,
T., Chem Res
Toxicol 2001, 14, 1139-1162.
8. Haung, R. H.; Faulkner, R. The role of phospholipid in the
multiple
functional forms of brain monoamine oxidase. J Biol Chem 1981,
256, 9211-
9215.
9. Cohen, G.; Farooqui, R.; Kesler, N., Parkinson disease: A new
link
between monoamine oxidase and mitochondrial electron flow. Proc
Natl Acad
Sci U.S.A. 1997, 94, 4890-4894.
10. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek,
F., Structure
and Mechanism of Monoamine Oxidase. Curr Med Chem 2004, 11,
1983-1993.
11. Youdim, M. B. H.; Finberg, J. P. M., New directions in
monoamine
oxidase A and B selective inhibitors and substrates. Biochem
Pharmacol 1991,
41, 155-162.
12. Gottowik, J.; Cesura, A. M.; Malherbe, P.; Lang, G.; Prada,
M. D.,
Characterisation of wild-type and mutant forms of human
monoamine oxidase
A and B expressed in a mammalian cell line. FEBS Lett 1993, 317,
152-156.
-
105
13. Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C., Substrate
and inhibitor
specificities for human monoamine oxidase A and B are influenced
by a single
amino acid. J Biol Chem 2001, 276, 9877-9882.
14. Westlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose,
R. M.; Abell,
C. W., Distinct monoamine oxidase A and B populations in primate
brain.
Science 1985, 230, 181-183.
15. Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.;
Bembenek, M.
E.; Kwan, S.W.; Seeburg, P. H.; Shih, J. C., cDNA cloning of
human liver
monoamine oxidase A and B: molecular basis of differences in
enzymatic
properties. Proc Natl Acad Sci U.S.A. 1988, 85, 4934-4938.
16. Grimsby, J.; Chen, K.; Wang, L. J.; Lan, N. C.; Shin, J. C.,
Human
monoamine oxidase A and B genes exhibit identical exon-intron
organization.
Proc Natl Acad Sci U.S.A. 1991, 88, 3637-3641.
17. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, DE.;
Mattevi, A.,
Structure of human monoamine oxidase B, a drug target for the
treatment of
neurological disorders. Nat Struct Biol 2002, 9, 22-26.
-
106
18. Youdim, M.B.H.; Finberg, J.P.M.; Tipton, K.F., Monoamine
oxidase. In:
Advances in Experimental Pharmacology. Catecholamine. II. ed.
Trendelenburg,
U. & Weiner, U., Berlin: Springer-Verlag. 1988, 119-192.
19. Finberg, J.P.; Tenne, M., selective inhibition of monoamine
oxidase types
A and B in the rat vas deferens. Br J Pharmacol 1982, 77,
13-21.
20. Finberg, J.P.; Tenne, M.; Youdim, M.B., Tyramine
antagonistic properties
of AGN 1135, an irreversible inhibitor of monoamine oxidase type
B. Br J
Pharmacol 1981, 73, 65-74.
21. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M.B.; Hars,
V.; Marton,
J., Increased life expectancy resulting from addition of
L-deprenyl to Madopar
treatment in Parkinson's disease: a longterm study. J Neural
Transm 1985, 64,
113-127.
22. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson,
DE.; Mattevi,
A., Three-dimensional structure of human monoamine oxidase A
(MAO A):
relation to the structures of rat MAO A and human MAO B. Proc
Natl Acad Sci
U.S.A 2005, 102, 12684-12689.
23. Binda, C.; Mattevi, A.; Edmondson, D E.,
Structure-function
relationships in flavoenzyme-dependent amine oxidations: a
comparison of
-
107
polyamine oxidase and monoamine oxidase. J Biol Chem 2002, 277,
23973-
23976.
24. National Institute of Neurological disorders and Stroke NIH
Institute,
Parkinson's Disease: Hope Through Research, 2008.
25. Magyar, K.; Pálfi, M.; Tábi, T.; Kalász, H.; Szende, B.;
Szöko, E.,
Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004, 11,
2017-2031.
26. Baumgarten, H.G.; Zimmermann, G., In Handbook of Exp.
Pharm.,
Springer-Verlag, 1992.
27. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I.,
Chronic Parkinsonism
in humans due to a product of meperidine-analog synthesis.
Science 1983,
219, 979-980.
28. Crossman, A. R.; Clarke, C. E.; Boyce, S.; Robertson, R. G.;
Sambrok, M.
A., MPTP-induced parkinsonism in the monkey: neurochemical
pathology,
complications of treatment and pathophysiological mechanisms.
Can J Neurol
Sci 1987, 14, 428-435.
29. Pifl, C.; Schingnitz, G.; Hornykievicz, O., The neurotoxin
MPTP does not
reproduce in the rhesus monkey the interregional pattern of
striatal dopamine
-
108
loss typical of human idiopathic Parkinson's disease. Neurosci
Lett 1988, 92,
228-233.
30. Chiba, K.; Trevor, A.; Castagnoli, N. Jr., Metabolism of the
neurotoxic
tertiary amine, MPTP, by brain monoamine oxidase. Biochem
Biophys Res
Commun 1984, 120, 574-578.
31. Dimonte, D. A.; Wu, E.Y.; Delanney, L. E.; Irwin, I.;
Langston, J.W.,
Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in
primary cultures of
mouse astrocytes. J Pharmacol Exp Ther 1992, 261, 44-49.
32. Pifl, C.; Giros, B.; Caron, M. G., Dopamine transporter
expression
confers cytotoxicity to low doses of the parkinsonism-inducing
neurotoxin 1-
methyl-4-phenylpyridinium. J Neurosci 1993, 13, 4246-4253.
33. Peter, D.; Dimenez, J.; Liu, Y.; Kim, J.; Edwards, R. H.,
The chromaffin
granule and synaptic vesicle amine transporters differ in
substrate recognition
and sensitivity to inhibitors. J Biol Chem 1994, 269,
7231-7237.
34. Lotharius, J.; O’Malley, K. L., The parkinsonism-inducing
drug 1-methyl-
4-phenylpyridinium triggers intracellular dopamine oxidation. A
novel
mechanism of toxicity. J Biol Chem 2000, 275, 38581-38588.
-
109
35. Nicklas,W. J.; Youngster, S. K.; Kindt, M. V.; Heikkila, R.
E., MPTP,
MPP+ and mitochondrial function. Life Sci. 1987, 40,
721-729.
36. Nakamura, K.; Bindokas, V. P.; Marks, J. D.; Wright, D. A.;
Frim, D. M.;
Miller, R. J.; Kang, U.J., The selective toxicity of
1-methyl-4-phenylpyridinium
to dopaminergic neurons: the role of mitochondrial complex I and
reactive
oxygen species revisited. Mol Pharmacol 2000, 58, 271.
37. Waldmeier, P. C.; Boulton, A. A.; Cools, A. R.; Kato, A. C.;
Tatton, W. G.,
Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural
Transm Suppl.
2000, 60, 197-214.
38. Waldmeier, P. C.; Spooren, W. P.; Hengerer, B., CGP 3466
protects
dopaminergic neurons in lesion models of Parkinson's disease.
Naunyn
Schmiedebergs Arch Pharmacol 2000, 362, 526-537.
39. Zimmermann, K.; Waldmeier, P.C., Tatton, W. G.,
Dibenzoxepines as
treatments for neurodegenerative diseases. Pure Appl Chem 1999,
71, 2039-
2046.
40. Langston, J. W.; Langston, E. B.; Irwin, I., MPTP-induced
parkinsonism
in human and non-human primates--clinical and experimental
aspects. Acta
Neurol. Scand. Suppl. 1984, 100, 49-54.
-
110
41. Ross, S. B.; Renyi, A.L., On the long-lasting inhibitory
effect of N-(2-
chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active
uptake of
noradrenaline. J Pharm Pharmacol 1976, 28, 458-459.
42. Finnegan, K. T.; Skratt, J. S.; Irwin, I.; DeLanney, L. E.;
Langston, J. W.,
Protection against DSP-4-induced neurotoxicity by deprenyl is
not related to its
inhibition of MAO B. Eur J Pharmacol 1990, 184, 119-126.
43. Ebadi, M.; Sharma, S.; Shavali, S.; El Refaey, H. J.,
Neuroprotective
actions of selegiline. Neurosci Res 2002, 67, 285-289.
44. Ricci, A.; Mancini, M.; Strocchi, P.; Bongrani, S.;
Bronzetti, E., Deficits in
cholinergic neurotransmission markers induced by ethylcholine
mustard
aziridinium (AF64A) in the rat hippocampus: sensitivity to
treatment with the
monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp Clin Res
1992, 18, 163-
171.
45. Youdim, M.B.; Bakhle, Y.S., Monoamine oxidase: isoforms and
inhibitors
in Parkinson's disease and depressive illness. Br J Pharmacol
2006, 147, S287-
S296.
-
111
46. Yong, N.H.; Shi, Y. R.; Byung, H. H., Antioxidant Activity
Resveratrol
Closely Correlates with Its Monoamine oxidase-A Inhibitory
Activity. Arch
Pharm Res 1990, 13, 132-135.
47. Osman, F. Guner.; Douglas, R. Henry. Metric for Analyzing
Hit Lists and
Pharmacophores. In Phamacophore Perception, Development, and Use
in Drug
Design, Osman F. Guner., Ed.; International University Line: La
Jolla,
California, 2000; pp 193-210.
48. Catalyst 4.11 User Guide, Accelrys Inc., San Diego, CA
92121, USA,
2005.
49. Debnath, A. K. Pharmacophore mapping of a series of
2,4-diamino-5-
deazapteridine inhibitors of Mycobacterium avium complex
dihydrofolate
reductase. J. Med. Chem. 2002, 45, 41-53.
50. Kurogi, Y.; Güner, O. F. Pharmacophore modeling and
three-
dimensionaldatabase searching for drug design using catalyst.
Curr. Med.
Chem. 2001, 8,1035–1055.
51. Johnston, JP., Some observations upon a new inhibitor of
monoamineoxidase in brain tissue. Biochem Pharmacol 1968, 17,
1285–1297.
-
112
52. Shih, JC.; Chen, K.; Ridd, MJ., Monoamine oxidase: from
genes
tobehavior. Annu Rev Neurosci 1999, 22, 197-217.
53. Fowler, JS.; Logan, J.; Wang, G.J.; Volkow, N.D.; Telang,
F.; Zhu, W.;
Franceschi, D.; Pappas, N.; Ferrieri, R.; Shea, C.;, Garza, V.;
Xu, Y.; Schlyer,
D.; Gatley, S.J.; Ding, Y.S.; Alexoff, D.; Warner, D.; Netusil,
N.; Carter, P.;
Jayne, M.; King, P.; Vaska, P., Low monoamine oxidase B in
peripheral organs
in smokers. Proc Natl Acad Sci U S A. 2003, 100 (20),
11600-11605.
54. Kumar, M.J.; Nicholls, D.G.; Andersen, J.K., Oxidative
alpha-
ketoglutarate dehydrogenase inhibition via subtle elevations in
monoamine
oxidase B levels results in loss of spare respiratory capacity:
implications for
Parkinson's disease. J Biol Chem 2003, 278 (47),
46432-46439.
55. Trendelenburg, U.; Weiner, N., Monoamine Oxidase, in: M.B.H.
Youdim,
J.P.M. Finberg, K.F. Tipton (Eds.), Advances in Experimental
Pharmacology,
Springer-Verlag, Berlin, 1988, 119–192.
56. Knoll, J.; Magyar, K., Some puzzling pharmacological effects
of
monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972,
5, 393-
408.
-
113
57. Bohm, H.J.; Flohr, A.; Stahl, M., Scaffold hopping, Drug
Discov Today
Technol, 2004, 1, 217–224.
58. Zhao, H., Scaffold selection and scaffold hopping in lead
generation: a
medicinal chemistry perspective. Drug Discov Today, 2007, 12,
149–155.
59. Ertl, P.;, Jelfs, S.; Mühlbacher, J.; Schuffenhauer, A.;
Selzer, P., Quest
for the rings. In silico exploration of ring universe to
identify novel bioactive
heteroaromatic scaffolds, J Med Chem, 2006, 49, 4568-4573.
60. Gritsch, S.; Guccione, S.; Hoffmann, R.; Cambria, A.;
Raciti, G.; Langer,
T., 3D QSAR study of monoamino oxidase-B inhibitors using the
chemical
function based pharmacophore generation approach, J Enzyme
Inhib, 2001,
16, 199–215.
61. Maestro, Version 1.0.9113, Schrodinger, L.L.C., New York,
2006.
62. Glide, Version 3.5, Schrodinger, L.L.C., New York, 2006.
63. Cerius2, Version 4.11, Accelrys Inc., San Diego, CA 92121,
USA, 2007.
64. Catalyst, Version 4.11, Accelrys Inc., San Diego, CA 92121,
USA, 2007.
-
114
65. Nesrin, G.; Akgul, Y.S.; Gulberk, U.; Kevser, E.; Altan,
A.B., 1-N-
Substituted Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines:
Synthesis and
Evaluation as MAO Inhibitors, Arch Pharm Pharm Med Chem, 2003,
336, 362–
371.
66. Herraiz, T.; Chaparro, C., Human monoamine oxidase is
inhibited by
tobacco smoke: beta-carboline alkaloids act as potent and
reversible inhibitors.
Biochem Biophys Res Commun, 2005, 326, 378–386.
67. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F., Inhibitory
effects of cis- and
trans-resveratrol on noradrenaline and 5-hydroxytryptamine
uptake and on
monoamine oxidase activity, Biochem Biophys Res Commun, 2006,
344, 688–
695.
68. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M., Eugenol and its
structural
analogs inhibit monoamine oxidase A and exhibit
antidepressant-like activity,
Bioorg Med Chem, 2005, 13, 4777–4788.
69. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti,
P.; Granese,
A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F., Synthesis
and molecular
modelling of novel substituted-4,5-dihydro-(1H)-pyrazole
derivatives as potent
and highly selective monoamine oxidase-A inhibitors, Chem Biol
Drug Des,
2006, 67, 206–214.
-
115
70. Hutchinson, D.K., Oxazolidinone antibacterial agents: a
critical review,
Curr Top Med Chem, 2003, 3, 1021–1042.
71. Rosen, T.C.; Yoshida, S.; Fröhlich, R.; Kirk, K.L.; Haufe,
G., Fluorinated
phenylcyclopropylamines. 2. Effects of aromatic ring
substitution and of
absolute configuration on inhibition of microbial tyramine
oxidase, J Med
Chem, 2004, 47, 5860–5871.
72. Hubálek, F.; Binda, C.; Li, M.; Herzig, Y.; Sterling, J.;
Youdim, M.B.;
Mattevi, A.; Edmondson, DE., Inactivation of purified human
recombinant
monoamine oxidases A and B by rasagiline and its analogues, J
Med Chem,
2004, 47, 1760–1766.
73. Wang, E.Y.; Gao, H.; Salter, C.L.; Zhang, J.; Huang, L.;
Podar, E.M.;
Miller, A.; Zhao, J.; O'rourke, A.; Linnik, M.D., J Med Chem,
2006, 49, 2166–
2173.
74. Debnath, A.K., Pharmacophore mapping of a series of
2,4-diamino-5-
deazapteridine inhibitors of Mycobacterium avium complex
dihydrofolate
reductase, J Med Chem, 2002, 45, 41–53.
-
116
75. Vadivelan, S.; Sinha, B.N.; Irudayam, S.J.; Jagarlapudi,
S.A., Virtual
screening studies to design potent CDK2-cyclin A inhibitors, J
Chem Inf Model,
2007, 47, 1526–1535.
76. Vadivelan, S.; Sinha, B.N.; Rambabu, G.; Boppana, K.;
Jagarlapudi, S.A.,
Pharmacophore modeling and virtual screening studies to design
some
potential histone deacetylase inhibitors as new leads, J Mol
Graph Model, 2008,
26, 935–946.
77. Vadivelan, S.; Sinha, B.N.; Sunita, T.; Sarma, J.A.R.P.,
Fragment and
knowledge-based design of selective GSK-3ß inhibitors using
virtual screening
models, Eur J Med Chem, 2009, 44, 2361-2371.
78. Guner, O.F.; Henry, D.R.; Phamacophore Perception,
Development, and
Use in Drug Design, Osman F. Guner (Ed.), International
University Line, La
Jolla, California, 2000, 193–210.
79. Berman, H. M.; Bhat, T. N.; Bourne, P. E.; Feng, Z.;
Gilliland, G.;
Weissig, H.; Westbrook, J. The Protein Data Bank and the
challenge of
structural genomics. Nature Struct. Biol. 2000, 7, 957–959.
80. Westbrook, J.; Feng, Z.; Chen, L.; Yang, H.; Berman, H. M.
The Protein
Data Bank and structural genomics. Nucleic Acid Res. 2003, 31,
489–491.
-
117
81 Blundell, TL.; Jhoti, H.; Abell, C. High-throughput
crystallography for
lead discovery in drug design. Nature Rev. Drug Discov. 2002, 1,
45–54.
82 Chen, H.; Lyne, P. D.; Giordanetto, F.; Lovell, T.; Li, J. On
evaluating
molecular-docking methods for pose prediction and enrichment
factors. J.
Chem. Inf. Model. 2006, 46, 401-415.
83. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual
screening of
chemical databases. 1. Evaluation of different docking/scoring
combinations.
J. Med. Chem. 2000, 43, 4759-4767.
84. Glen, R. C.; Allen, S. C. Ligand-protein docking: cancer
research at the
interface between biology and chemistry. Curr. Med. Chem. 2003,
10, 763-777.
85. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J.
Docking and
scoring in virtual screening for drug discovery: methods and
applications. Nat.
Rev. Drug Discovery, 2004, 3, 935-949.
86. Ingo, Muegge.; Istvan, J. Enyedy. Virtual Screening of
Kinase Targets.
Curr. Med. Chem. 2004, 11, 693-707.
-
118
87. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat,
T. N.;
Weissig, H.; Shindyalov I. N.; Bourne P. E. The Protein Data
Bank. Nucleic
Acids Res. 2000, 28, 235-242.
88. Gohlke, H.; Klebe, G. Statistical potentials and scoring
functions applied
to protein-ligand binding. Curr. Opin. Struct. Biol. 2001, 11,
231–235.
89. Marcel, L. Verdonk.; Jason, C. Cole.; Michael, J.
Hartshorn.;
Christopher, W. Murray.; Richard, D. Taylor. Improved
protein-ligand docking
using GOLD. Proteins: Structure, Function, and Genetics 2003,
52, 609–623.
90. Bartosz, A. Grzybowski.; Alexey, V. Ishchenko.; Chu-Young
Kim.; George
Topalov.; Robert Chapman.; David, W. Christianson.; George, M.
Whitesides.;
Eugene, I. Shakhnovich. Combinatorial computational method gives
new
picomolar ligands for a known enzyme. J. Comput.-Aided Mol.
Des., 1997, 11,
425-445.
91. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead D. R.;
Eldridge, M.
D. Flexible Docking Using Tabu Search and an Empirical Estimate
of Binding
Affinity. Proteins, 1998, 33, 367-382.
92. Glide, version 3.5; Schrodinger, L.L.C., New York, 2006.
-
119
93. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T.
A.; Klicic, J. J.;
Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry,
J. K.; Shaw, D.
E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid,
accurate
docking and scoring. 1. Method and assessment of docking
accuracy. J. Med.
Chem. 2004, 47, 1739-1749.
94. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H.
S.; Frye, L. L.;
Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid,
accurate docking
and scoring. 2. Enrichment factors in database screening. J.
Med. Chem. 2004,
47, 1750-1759.
95. Cerius2 4.11 User Guide, Accelrys Inc., San Diego, CA 92121,
USA,
2005.
96. Hodgson, J., ADMET--turning chemicals into drugs. Nat
Biotechnol
2001, 19, (8), 722-6
97. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.;
Salvati, P.;
Edmondson, D.E.; Mattevi, A., Structures of human monoamine
oxidase B
complexes with selective noncovalent inhibitors: safinamide and
coumarin
analogs, J Med Chem, 2007, 50, 5848–5852.
-
120
98. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat,
T.N.; Weissig,
H.; Shindyalov, I.N.; Bourne, P.E., The Protein Data Bank,
Nucleic Acids Res,
2000, 28, 235–242.
99. Barros, A. I. R. N. A.; Silva, A. M. S.; Alkorta, I.;
Elguero, J. Synthesis,
experimental and theoretical NMR study of 2’-hydroxychalcones
bearing a nitro
substituent on their B ring, Tetrahedron, 2004, 60,
6513-6521.
100. Sharma, T. C.; Saksena, V.; Reddy, N. J., Oxidation of
some
hydroxyarylpyrazolines with manganese dioxide, Acta Chim. Acad.
Sci. Hungar.,
1977, 93, 415-419.
101. Gokhan, N.; Yesilada, A.; Ucar, G.; Erol, K.; Bilgin, A.
A., 1-N-Substituted
Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and
Evaluation as
MAO Inhibitors, Arch. Pharm. (Weinheim, Ger.) 2003, 336,
362-371.
102. Holt, A.; Sharman, D. F.; Baker, G. B.; Palcic, M. M., A
continuous
spectrophotometric assay for Monoamine Oxidase and related
enzymes in
tissue homogenates, Anal. Biochem. 1997, 244, 384-392.
103. Bradford, M. M. A, rapid and sensitive method for the
quantitation of
microgram quantities of protein utilizing the principle of
Protein-Dye Binding,
Anal. Biochem. 1976, 72, 248-254.